NCT05062421 Persistence of Biological Treatment and Inhibitors of Jak Kinases in Patients With Rheumatoid Arthritis.
| NCT ID | NCT05062421 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla |
| Condition | Arthritis, Rheumatoid |
| Study Type | OBSERVATIONAL |
| Enrollment | 540 participants |
| Start Date | 2021-04-01 |
| Primary Completion | 2026-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 540 participants in total. It began in 2021-04-01 with a primary completion date of 2026-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
One-center observational study aimed at determining the survival of patients with rheumatoid arthritis treated with targeted synthetic disease-modifying drugs (FAMEsd) and biologic disease-modifying drugs (FAMEb). These patients will be administered a series of medications and a follow-up will be carried out to analyze their evolution.
Eligibility Criteria
Inclusion Criteria: * Patients aged ≥18 years. * With a diagnosis of Adult Rheumatoid Arthritis according to the 2010 ACR / EULAR criteria. * Who have received at least one of the doses of the study drugs. * In follow-up in the consultations of the UGC of Rheumatology of the HUVM. * With at least two complete evaluations (baseline and final) of clinical variables. Exclusion Criteria: * Patients where the medical records lack sufficient baseline and final variables to perform the analysis. * Patients in whom more than 50% of the variables to be collected are missing in the data collection.
Contact & Investigator
Blanca Estela Hernández Cruz
PRINCIPAL INVESTIGATOR
Hospital Universitario Virgen Macarena
Frequently Asked Questions
Who can join the NCT05062421 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Arthritis, Rheumatoid. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05062421 currently recruiting?
Yes, NCT05062421 is actively recruiting participants. Contact the research team at blancahcruz@gmail.com for enrollment information.
Where is the NCT05062421 trial being conducted?
This trial is being conducted at Seville, Spain.
Who is sponsoring the NCT05062421 clinical trial?
NCT05062421 is sponsored by Fundación Pública Andaluza para la gestión de la Investigación en Sevilla. The principal investigator is Blanca Estela Hernández Cruz at Hospital Universitario Virgen Macarena. The trial plans to enroll 540 participants.